AB0031 IL-2 THERAPY AFFECT PERIPHERAL BLOOD LYMPHOCYTE LEVEL IN PATIENTS WITH PRIMARY SJöGREN’S SYNDROME

Background: PrimarySjogren’sSyndrome (PSS )is a chronic inflammatory autoimmune disease that mainly involves exocrine glands. Changes in the number of lymphocytes in PSS due to broken immune balance. Objectives: Toexplorethe quantitative changes of peripheral Th17 cells and regulatory T cells (Tregs) in primarySjogren’ssyndrome before and after short-term low doseIL-2 treatment, and to explore the correlation between the level of peripheral blood lymphocytes and clinical indexes in patients with primary Sjogren syndrome. Methods: Total172PSSpatients were enrolled,and 196 healthy adults were used as normal controls.Of them,53 cases were treated with low dose IL-2(5.0*105 international units (IU) for 5 days).The median four quantile method was used for statistical description. Multiple samples were compared with Kruskal-Wallis H test, and the correlation between variables was Spearman rank correlation analysis. Results: (1 )The number ofT,Th1 cells were decreased as compared with that in the control group(p 0.05). (2) The Th17 cell levels, the ratio of Th17/Treg and CD4+ T/CD8+ T were negatively correlated with ESR (p Conclusion: The level of CD4 + T cells in peripheral blood of patients with PSS such as T,Th1,Th17,Treg cells were significantly decreased, Th17,Th17/Tregwere correlated with ESR,CRP.however, Th17,Treg cell levelswere increased after treatment with short term low dose IL-2,especially Treg cells .Itindicated that IL-2 promoted the differentiation of Treg cells, maintained the function of Treg cells. References [1] Furuzawa-Carballeda J, Hernandez-Molina G, Lima G, et al. Peripheral regulatory cells immunophenotyping in PSS: a cross-sectional study. Arthritis Res Ther2013;15:R68 Disclosure of Interests: None declared